

PRESS RELEASE

Intrasense obtains a new patent and consolidates its portfolio of technologies

A new patented technique for virtual colonoscopy in colon cancer diagnosis and follow-up

Paris, June 10 2014: Intrasense (FR0011179886 – ALINS), a leader in multimodal medical imaging software, announces today that it has been granted a European patent (EP2339538)¹ for its invention allowing the production of *filet views* with reduced artefacts in virtual CT colonoscopy.

Virtual colonoscopy is a solution for colon cancer screening and diagnosis used as an alternative to optical devices, which are more invasive and expensive. It allows the evaluation of the total colon lumen without sedation or anesthesia and is a more comfortable option for patients whenever applicable.

This innovative technology provides a high quality rendering of the colon for optimized visualization and reliable cancer screening, diagnosis and follow-up. It streamlines the reading process and helps look behind the folds of the colon in a single fly-through exploration.

Myrian® is the ultimate solution for image-based diagnosis and follow-up in oncology. The new patented technique is soon to be implemented in Myrian® XP-Colon, allowing reduced interpretation time, accurate virtual colonoscopy and easy navigation inside the colon to diagnose cancer and search for polyps.

Colorectal cancer being the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012², this patent opens up significant market opportunities, especially as an increasing number of developed countries have been implementing early colon cancer screening operations and are progressively adopting virtual colonoscopy.

Frédéric Banégas, Intrasense chief operating officer, underlines: *“This patent is a new highlight of Intrasense innovation capabilities. It further demonstrates how the combination of industrial, clinical and academic backgrounds within our multidisciplinary team fosters creativity and breakthrough technology. It is another evidence of the powerful translational capability of our company, a recognized leader in oncology imaging, and reinforces our technology portfolio.”*

About Intrasense:

Created in 2004 with an innovative technology of tissues detection in CT scan, Intrasense designs, develops and markets Myrian®, a unique, vendor-neutral software suite for the visualization and advanced processing of multimodal medical images such as MRI, CT scans, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian® combines and uses all of the various medical images to extract information vital to the patient's care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 - ALINS). The company employs 70 people, including 25 dedicated in R&D. Labelled “innovative company” by Oseo, Intrasense has invested over 9 M€ in R&D since its creation.

For more about Intrasense, please visit www.intrasense.fr and follow us on [LinkedIn](#).

PRESS RELEASE

1 *Artifact-free filet view for virtual endoscopy of lumen structures*, EP2339538 (A1) — 2011-06-29; Banegas F., Spuhler C., Caderas de Kerleau C., Moulis M.; Intrasense (France), May 2014.

2 World Cancer Research Fund International,
http://www.wcrf.org/cancer_statistics/data_specific_cancers/colorectal_cancer_statistics.php



CONTACTS

Intrasense
Patrick Mayette
Chief Executive Officer
Christophe Lamboeuf
Chief Financial Officer
Phone: (33) (0)1 48 04 32 83
investor@intrasense.fr

NewCap.
Financial disclosure and investor relations
Valentine Brouchet / Pierre Laurent
Phone: (33) (0)1 44 71 94 96
intrasense@newcap.fr